A U.S. advisory panel voted 14-10 that Pfizer Inc.'s pain reliever Bextra should stay on the market, an agency spokeswoman said. Eight members of the Food and Drug Administration advisory committee abstained from voting, the spokeswoman said. --SP 2326 Local Time 2026 GMT